Navigation Links
Bayer Wins Positive Response For Marketing Its Cancer Drug

European officials have given the green signal for Bayer AG and its partner Onyx Pharmaceuticals Inc., for marketing their new drug to treat kidney cancer//.

The opinion of the European Committee for Medicinal Products for Human Use (CHMP) of the drug Nexavar would now be passed onto the European Commission.

A positive ruling by the commission could pave the way for a marketing authorisation for all EU nations in the second half of this year.

The announcement coincided with Bayer's annual general meeting in Cologne, where the group's chief Werner Wenning sought to secure shareholders' support for the planned 16.5 billion euros ($21 billion) takeover of rival pharmaceuticals firm Schering AG.

Describing the proposed acquisition as a milestone in the company's history, Wenning said that this move was the "right step" for the group.

The takeover, Wenning said, would propel Bayer into "the top league of pharmaceutical makers around the world".

Wenning went on to tell the company's shareholders that the acquisition would result in the health services section emerging as the key engine for growth.

Bayer's 86-euro a share offer for Berlin based Schering runs until the end of May with the takeover representing the biggest acquisition in Bayer's corporate history.

--Edited IANS
'"/>




Page: 1

Related medicine news :

1. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
2. Genomatix Licensed By Bayer Healthcare
3. Bayer to Market Biocon Insulin in China
4. Test for Esophageal Reflux Licensed to Bayer by University
5. The Positive Effects Of A Healthy Lifestyle
6. The Positive Effects Of A Healthy Lifestyle
7. Positive Thinking
8. Ruling On Non Disclosure Of HIV Positive Status Is Not Ethical
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. HIV Positive People Touching 60,000 In UK
11. Russian Miss HIV Positive Says Victims Are Treated Like Prostitutes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: